Assembly Biosciences (ASMB) EBITDA (2010 - 2026)

Assembly Biosciences' EBITDA history runs 17 years deep, the most recent figure standing at -$11.4 million for Q1 2026.

• In Q1 2026, EBITDA fell 14.37% year-over-year to -$11.4 million; the TTM figure through Mar 2026 stood at -$13.5 million (up 69.65% YoY), while the FY2025 annual figure was -$12.1 million, up 73.32% from the prior year.
• EBITDA for Q1 2026 stood at -$11.4 million, down from $19.8 million in the prior quarter.
• The five-year high for EBITDA was $19.8 million in Q4 2025, with the low at -$24.6 million in Q2 2022.
• The 5-year median for EBITDA is -$12.2 million (2024), against an average of -$13.4 million.
• The sharpest annual moves came in 2022 and 2025: EBITDA slipped 23.98% in 2022, then surged 271.69% in 2025.
• Assembly Biosciences' EBITDA stood at -$23.0 million in 2022, then soared by 45.38% to -$12.6 million in 2023, then grew by 8.12% to -$11.5 million in 2024, then soared by 271.69% to $19.8 million in 2025, then plunged by 157.43% to -$11.4 million in 2026.
• Business Quant data shows ASMB's EBITDA at -$11.4 million in Q1 2026, $19.8 million in Q4 2025, and -$10.9 million in Q3 2025.